Elite Pharmaceuticals sells rights to generic Sabril (vigabatrin) ANDA to Pyros

ELITE PHARMACEUTICALS INC /NV/

Sale of rights to approved ANDA for generic Sabril (Vigabatrin Powder for Oral Solution, 500 mg) to Pyros Pharmaceuticals.
Elite executed a three-year manufacturing and supply agreement with Pyros for the product.
Elite will be compensated at an agreed-upon price for manufacturing and packaging.
Agreement executed November 21, 2022; sale has been consummated.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ELITE PHARMACEUTICALS INC /NV/ entered into Manufacturing and Supply Agreement with Pyros Pharmaceuticals, Inc. (effective 2022-11-21).

Action: entry
Agreement: supply
Counterparty: Pyros Pharmaceuticals, Inc.
Effective: 2022-11-21

Exact text from the filing

collectively “Elite”) executed an agreement with Pyros Pharmaceuticals, Inc. (“Pyros”) pursuant to which the Company will sell to Pyros its rights in and to the Company’s approved abbreviated new drug applications (ANDAs) for its generic

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ELITE PHARMACEUTICALS INC /NV/ entered into a asset purchase with Pyros Pharmaceuticals, Inc. (effective 2022-11-21).

Action: entry
Agreement: asset purchase
Counterparty: Pyros Pharmaceuticals, Inc.
Effective: 2022-11-21

Exact text from the filing

On November 21, 2022, Elite Pharmaceuticals, Inc., and Elite Laboratories, Inc. (a wholly owned subsidiary of Elite Pharmaceuticals, Inc.) (collectively “Elite”) executed an agreement with Pyros Pharmaceuticals, Inc. (“Pyros”) pursuant to which the Company will sell to Pyros its rights in and to the Company’s approved abbreviated new drug applications (ANDAs) for its generic Sabril® (Vigabatrin Powder for Oral Solution, 500 mg) (“Product”).

View on SEC.gov

Browse all material agreements →

ELITE PHARMACEUTICALS INC /NV/ filing history →

Source: SEC EDGAR

accession 0001493152-22-033823

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.